Co-Authors
This is a "connection" page, showing publications co-authored by EDMUND SCOTT KOPETZ and THOMAS A ALOIA.
Connection Strength
0.319
-
Return to intended oncologic treatment (RIOT): a novel metric for evaluating the quality of oncosurgical therapy for malignancy. J Surg Oncol. 2014 Aug; 110(2):107-14.
Score: 0.119
-
Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg. 2015 Sep; 102(10):1175-83.
Score: 0.032
-
Is complete liver resection without resection of synchronous lung metastases justified? Ann Surg Oncol. 2015 May; 22(5):1585-92.
Score: 0.031
-
RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013 Oct; 258(4):619-26; discussion 626-7.
Score: 0.029
-
Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy. Ann Surg. 2013 Jun; 257(6):1079-88.
Score: 0.028
-
Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol. 2012 Dec 20; 30(36):4566-72.
Score: 0.027
-
Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. Ann Surg. 2012 Oct; 256(4):642-50.
Score: 0.027
-
KRAS mutation in colorectal cancer metastases after adjuvant FOLFOX for the primary. Br J Cancer. 2012 Oct 09; 107(8):1442-3; author reply 1444.
Score: 0.027